货号（Catalog No.）

CSD00400

通用名INN

Risankizumab

纯度(Purity)

>95%

浓度( Concentration)

1mg/ml

Formulation

PBS buffer PH7.5

Source

CHO cells

内毒素(Endotoxin level)

Please contact with the lab for this information.

生物活性

产品描述(Description)

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). On April 23, 2019 it was approved by the FDA (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults who are clinically considered eligible for systemic therapy or phototherapy for psoriasis.Label This drug has been commercialized through collaboration between the German pharmaceutical company, Boehringer Ingelheim, and Abbvie.

别名(Alternative names)

BI 655066,risankizumab-rzaa

靶点;物种(Specificity target name;species)

IL23A[Homo sapiens]

种类(Species)

Humanized

受体鉴定(Receptor identification)

IgG1-kappa

化学信息

CAS

1612838-76-2

存储条件(Storage)

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.

Note

For research use only .